Concordance of NOPR Post-PET Treatment Plans and Claims-Inferred Care
| NOPR treatment plan | Cancer type | Imaging indication | No. of patients | Agreement (%) | 95 confidence interval of agreement (%) | Other treatments | No treatment claims |
| Surgery | Lung | IS | 25 | 19 (76.0) | 54.9–90.6 | * | * |
| Other | IS | 130 | 98 (75.4) | 67.1–82.5 | 21 (16.1) | 11 (8.5) | |
| Prostate | IS | 506 | 298 (58.9) | 54.5–63.2 | 183 (36.1) | 27 (5.3) | |
| Chemotherapy ± other | Lung | IS | 148 | 120 (81.0) | 73.8–87.1 | 20 (13.5) | * |
| Lung | FOM | 136 | 100 (73.5) | 65.3–80.7 | 12 (8.8) | 24 (17.6) | |
| Chemotherapy only | Other | IS | 111 | 77 (69.4) | 59.9–77.8 | 16 (14.4) | 18 (16.2) |
| FOM | 228 | 154 (67.5) | 61.0–73.6 | 19 (8.3) | 55 (24.1) | ||
| Radiation | Lung | IS‡ | 80 | 67 (83.7) | 73.8–91.1 | * | * |
| FOM‡ | 36 | 26 (72.2) | 54.8–85.8 | * | * | ||
| Other | IS† | 30 | 24 (80.0) | 61.4–92.3 | * | * | |
| FOM† | 54 | 40 (74.0) | 60.3–85.0 | * | * | ||
| FOM‡ | 59 | 36 (61.0) | 47.4–73.4 | * | * | ||
| Prostate | IS† | 729 | 616 (84.4) | 81.7–87.1 | 75 (10.3) | 38 (5.2) | |
| FOM† | 422 | 289 (68.4) | 63.8–72.9 | 60 (14.2) | 73 (17.3) | ||
| ADT only | Prostate | IS | 308 | 265 (86.0) | 81.7–89.7 | 27 (8.8) | 16 (5.2) |
| FOM | 1,088 | 895 (82.3) | 79.9–84.5 | 36 (3.3) | 157 (14.4) | ||
| ADT + radiation | Prostate | ||||||
| ADT component | IS | 517 | 418 (80.8) | 77.2–84.1 | 17 (3.3) | 15 (2.9) | |
| FOM | 271 | 205 (75.6) | 70.1–80.6 | * | 29 (10.7) | ||
| Radiation component | IS | 517 | 424 (82.0) | 78.4–85.2 | 17 (3.3) | 15 (2.9) | |
| FOM | 271 | 183 (67.5) | 61.6–73.1 | * | 29 (10.7) |